Autopsy report · NCT01386398

Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

“Company withdrew interest”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Sponsor type

University, hospital or other

Conditions

Lymphoma

Interventions

bortezomib; vorinostat; laboratory biomarker analysis

Participants

0

Trials that died the same way

• SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
  “Supporting company withdrew interest” (93% match in meaning)
• The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU
  “Withdrawn due to no funding” (65% match in meaning)
• Lucentis for New Onset Neovascular Glaucoma
  “Company withdrew funding/sponsorship” (65% match in meaning)
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  “funding was withdrawn” (64% match in meaning)
• Awbat Versus Biobrane in Partial Thickness Burns
  “Company went out of business” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.